Skip to search formSkip to main contentSkip to account menu

SHP099

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PiperidinesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract P3-10-20: Targeting the tyrosine phosphatase SHP2 is efficacious against HER2-positive breast cancer
Accumulating evidence suggests that the Src homology phosphotyrosyl phosphatase 2 (SHP2) is a bona fide oncogene. These… 
2019
2019
Design, Synthesis, and In Vitro Activity of Pyrazine Compounds
Despite the fact that there are several anticancer drugs available, cancer has evolved using different pathways inside the cell… 
2019
2019
Abstract LB-119: SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors
Deregulated RTK/RAS/RAF/MEK/ERK signaling (MAPK signaling) drives growth of over 40% of human tumors, most commonly due to… 
2019
2019
Abstract LB-259: FGFR- and EGFR-driven SHP2 activation displays differential sensitivity to allosteric SHP2 inhibition
Introduction: The non-receptor protein tyrosine phosphatase SHP2 mediates RAS activation downstream of various receptor tyrosine… 
2019
2019
Abstract 1773: The tyrosine phosphatase, SHP-2, is involved in regulating PD-L1 expression in non-small cell lung cancer
  • Keller Toral
  • Molecular and Cellular Biology / Genetics
  • 2019
  • Corpus ID: 198269756
Immune checkpoint inhibitors (ICIs), specifically those which target the T-cell surface receptor Programmed Cell Death-1 (PD-1… 
2019
2019
Abstract LB-005: Allosteric SHP2 phosphatase inhibition: Multiple mechanisms and chemotypes
Protein tyrosine phosphatase SHP2 is an oncoprotein associated with cancer as well as a potential immune modulator due to its… 
2018
2018
Abstract 4879: Mutation selectivity of the allosteric SHP2 inhibitor SHP099
SHP2 (PTPN11) mediates oncogenic signaling and gain-of-function (GOF) SHP2 mutations are associated with leukemias and other… 
2017
2017
Abstract 1176: Preclinical characterization of the pharmacokinetic-pharmacodynamics-efficacy relationship of novel allosteric SHP2 inhibitors
SHP2 is a non-receptor protein tyrosine phosphatase downstream of receptor tyrosine kinases (RTK). Mutations yielding… 
2017
2017
Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)
Despite development of highly potent and selective inhibitors (e.g., ceritinib, alectinib, lorlatinib) targeting anaplastic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)